• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

Recent Advances in the Study of 5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (CAS: 799270-07-8) in Chemical Biology and Pharmaceutical Research

The compound 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (CAS: 799270-07-8) has recently emerged as a key scaffold in medicinal chemistry and drug discovery. This heterocyclic structure, belonging to the pyrrolopyridine family, has attracted significant attention due to its versatile pharmacological properties and potential applications in targeting various disease pathways. Recent literature highlights its role as a privileged structure in kinase inhibitor development, particularly for oncology targets.

Structural analysis reveals that the bromo-substitution at the 5-position and the cyano group at the 3-position contribute to enhanced binding affinity and selectivity in protein-ligand interactions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this core structure show promising inhibitory activity against JAK family kinases, with IC50 values in the low nanomolar range. The electron-withdrawing nature of the cyano group appears to facilitate hydrogen bonding with key residues in the ATP-binding pocket.

In synthetic chemistry advancements, researchers have developed novel palladium-catalyzed cross-coupling reactions to functionalize the 5-bromo position, enabling rapid generation of diverse analogs. A recent Nature Communications paper (2024) described an efficient Suzuki-Miyaura coupling protocol that maintains the integrity of the sensitive pyrrolopyridine core while allowing introduction of various aryl and heteroaryl groups at the 5-position.

Pharmacokinetic studies of 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile derivatives have shown improved metabolic stability compared to earlier generation inhibitors. The presence of the cyano group appears to reduce oxidative metabolism by cytochrome P450 enzymes, as evidenced by in vitro microsomal stability assays. This property makes it particularly valuable for developing orally bioavailable therapeutics.

Current clinical applications under investigation include its use as a key intermediate in the synthesis of third-generation EGFR inhibitors for non-small cell lung cancer. Several pharmaceutical companies have incorporated this scaffold into their drug discovery pipelines, with at least two candidates currently in Phase I clinical trials for hematological malignancies.

Future research directions focus on exploring the scaffold's potential in targeted protein degradation (PROTACs) and covalent inhibitor design. The bromo-substituent offers a convenient handle for further derivatization, while the electron-deficient nature of the core structure makes it suitable for developing reversible covalent inhibitors. These developments position 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile as a versatile building block in modern drug discovery.

• 1207626-30-9(5-Bromo-3,4-dimethyl-1H-pyrrolo[2,3-b]pyridine)
• 4414-89-5(1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile)
• 1190312-91-4(3-Bromo-5-cyano-4-methyl-7-azaindole)
• 1111637-94-5(5-Bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine)
• 875639-71-7(5-bromo-3-phenyl-1H-pyrrolo[2,3-b]pyridine)
• 1207625-52-2(5-Bromo-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile)
• 889943-22-0(1H-Pyrrolo[2,3-b]pyridine-3,5-dicarbonitrile)
• 1159982-14-5(4-Bromo-1H-pyrrolo[2,3-B]pyridine-3-carbonitrile)
• 1190314-41-0(3-Bromo-5-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1000340-54-4(3-Bromo-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile)